Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 20...
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: GlobeNewswire
THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming medical meetings. Two studies will be presented at the American Heart Association’s (AHA) Scientific Sessions 2025, being held November 7-10 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online, while the third study will be presented at the Hypertrophic Cardiomyopathy Society (HCMS) Scientific Sessions, which this year is conducting its conference at AHA’s Scientific Sessions. “We believe that these presentations will further position sotagliflozin, a dual SGLT 1 and 2 inhibitior, as a class of medication different from any other on the market,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “As additional data is presented at December’s CVCT 2025 and beyond, we expect to build on the compelling findings being pre
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum [Yahoo! Finance]Yahoo! Finance
- Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists ForumGlobeNewswire
- Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well [Seeking Alpha]Seeking Alpha
- Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development [Yahoo! Finance]Yahoo! Finance
LXRX
Earnings
- 11/6/25 - Beat
LXRX
Sec Filings
- 11/10/25 - Form 8-K
- 11/6/25 - Form 424B5
- 11/6/25 - Form 8-K
- LXRX's page on the SEC website